A fund aiming to invest 1 billion dollars in innovative solutions against antimicrobial resistance has selected fund support provider Vistra as a strategic partner. AMR Action Fund is formed by four heavyweights including the pharmaceuticals industry’s global association and the World Health Organization.
The Vistra group, based in Hong Kong but manning offices in 45 jurisdictions, is the administrator of assets worth $370 billion dollars. Under the new strategic partnership with the AMR Action Fund, another billion is expected, according to Vistra’s press release.
With the purpose of enabling the market launch of 2–4 new antibiotics before 2030, the fund has been founded by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), in collaboration with the World Health Organization, the European Investment Bank, and the Wellcome Trust.
